Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.

ABSTRACT:

Background

Recent studies have demonstrated that high-dose corticosteroids and second-line immunosuppressants may impair survival of patients with immune-related adverse events (irAEs) upon treatment with immune checkpoint inhibitors (ICIs). In non-small-cell lung cancer (NSCLC), this has not been studied in sufficiently powered studies. This study assessed the association of corticosteroid dose and second-line immunosuppressants for irAEs with survival outcomes in patients with stage IV NSCLC treated with ICIs.

Patients and methods

Patients with stage IV NSCLC treated with ICI-based regimens between 2015 and 2022 in the first or second line who received systemic immunosuppressants for irAEs were retrospectively included from 17 hospitals in eight countries worldwide. Associ

SUBMITTER: van Dijk EJ 

PROVIDER: S-EPMC12857322 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature